Monitor for the permanent CFO appointment and any potential impact on financial reporting cadence, but this filing alone is routine for a micro-cap biotech. No immediate trading catalyst.
PDSB drugs
PDSB drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 20 $0.2089entry
- T+1 · 3mo ago +4.60%α +4.19% · $0.2185
- T+5 · 3mo ago +4.31%α +3.19% · $0.2179
- T+20 · 2mo ago +285.59%α +285.59% · $0.8055
- T+60 · 4d ago +317.71%α +318.79% · $0.8726
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
PDS Biotechnology Corp disclosed the resignation of CFO Lars Boesgaard, effective September 12, 2026, to pursue other professional endeavors, with no disagreement cited. The company appointed Controller Janetta Trochimiuk as interim Principal Accounting Officer and CEO Frank Bedu-Addo as interim Principal Financial Officer, effective the same date. This is a routine CFO departure with internal replacements named, carrying no material financial impact for a $12M market cap biotech.
Key Facts
- CFO Lars Boesgaard resigned effective September 12, 2026, to pursue other professional endeavors.
- Resignation is not due to any disagreement with company operations, policies, or practices.
- Janetta Trochimiuk, Controller, appointed interim Principal Accounting Officer effective September 12, 2026.
- CEO Frank Bedu-Addo appointed interim Principal Financial Officer effective September 12, 2026.
- Trochimiuk will continue at $279,519.57 annual base salary with no equity awards in connection with promotion.
Financial Impact
No material financial impact; CFO departure with internal replacements at disclosed salary of $279,519.57/year
Risk Factors
- Extended CFO vacancy could strain financial reporting if interim arrangement persists
- No permanent CFO search timeline disclosed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-033749 |
| Document: 0001140361-26-033749-index-headers.html | 0001140361-26-033749 |
| Document: 0001140361-26-033749-index.html | 0001140361-26-033749 |
| Document: 0001140361-26-033749.txt | 0001140361-26-033749 |
Track record
28 reports on PDSB
7 of 14 bullish or bearish reports moved the stock their way by T+20. Best: +71.95% at T+20 after the Jul 22, 2026 report. 11 of 14 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $0.8726 Now $0.9240 +5.89% settles Dec 14
- Nov 12, 20264d ago SC 13D/A Neutral 4/10 Entry $0.9800 Now $0.9240 −5.71% settles Dec 11
- Nov 10, 20266d ago 8-K Neutral 4/10 Entry $1.03 Now $0.9240 −10.29% settles Dec 9
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 4/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.9605 Now $0.9240 −3.80% settles Nov 17
- Oct 14, 20264w ago S-3 Bearish 7/10 Entry $1.30 to $0.9800 Now $0.9240 +28.92% ▲ +24.62% +22.71% vs SPY
- Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.05 to $1.41 Now $0.9240 −11.58% ▲ +34.93% +38.10% vs SPY
- Sep 22, 20267w ago 8-K Bullish 6/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
- Sep 22, 20267w ago Press Release Bullish 7/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers